Published online before print February 16, 2004, doi: 10.1161/01.CIR.0000118466.47982.CC
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:1789-1794.)
© 2004 American Heart Association, Inc.
Basic Science Reports |
Protective Effects of Endogenous Adrenomedullin on Cardiac Hypertrophy, Fibrosis, and Renal Damage
From the Department of Cardiovascular Medicine (P.N., T.S., H.I., S.I., N.T., Y.Z., A.E., Y.H., R.N.) and Cardiothoracic Surgery (Y.S.), Graduate School of Medicine, University of Tokyo, Tokyo, Japan, and National Cardiovascular Center Research Institute (K.K.), Osaka, Japan.
Correspondence to Takayuki Shindo, MD, PhD, Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. E-mail shindo-tky{at}umin.ac.jp
Received May 22, 2003; de novo received September 8, 2003; revision received November 11, 2003; accepted November 20, 2003.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Adrenomedullin (AM) is a novel vasodilating peptide thought to have important effects on cardiovascular function. The aim of this study was to assess the activity of endogenous AM in the cardiovascular system using AM knockout mice.
Methods and Results— Mice heterozygous for an AM-null mutation (AM+/–) and their wild-type littermates were subjected to aortic constriction or angiotensin II (Ang II) infusion. The resultant cardiovascular stress led to increases in heart weight/body weight ratios, left ventricular wall thickness, and perivascular fibrosis, as well as expression of genes encoding angiotensinogen, ACE, transforming growth factor-ß, collagen type I, brain natriuretic peptide, and c-fos. In addition, renal damage characterized by decreased creatinine clearance with glomerular sclerosis was noted. In all cases, the effects were significantly more pronounced in AM+/– mice. Hearts from adult mice subjected to aortic constriction showed enhanced extracellular signal-regulated kinase (ERK) activation, as did cardiac myocytes from neonates treated acutely with Ang II. Again the effect was more pronounced in AM+/– mice, which showed increases in cardiac myocyte size, protein synthesis, and fibroblast proliferation. ERK activation was suppressed by protein kinase C inhibition to a greater degree in AM+/– myocytes. In addition, treatment of cardiac myocytes with recombinant AM suppressed Ang II-induced ERK activation via a protein kinase A-dependent pathway.
Conclusions— Endogenous AM exerts a protective effect against stress-induced cardiac hypertrophy via protein kinase C- and protein kinase A-dependent regulation of ERK activation. AM may thus represent a useful new tool for the treatment of cardiovascular disease.
Key Words: peptides • angiotensin • cardiovascular diseases • hypertrophy • kidney
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Adrenomedullin (AM) is a vasodilator peptide originally isolated from the extract of human pheochromocytoma.1 It has also been shown to be produced in vascular endothelial and smooth muscle cells and in cardiac myocytes,2,3 and high levels are found in the heart, lung, kidney, and adrenal medulla.4 In addition to its ability to reduce vascular tone, it stimulates hormone secretion5 and cell growth and differentiation.6,7 AM appears to circulate in plasma and has been implicated in the regulation of cardiovascular function.8,9 Indeed, plasma and tissue levels of AM are increased in patients with such cardiovascular ailments as hypertension, congestive heart failure, myocardial infarction, and renal dysfunction.9,10 This led us to hypothesize that AM participates in the pathophysiology of cardiovascular disease, although it is not clear whether its effects are causative or compensatory.
Cardiac hypertrophy, which is recognized in many cardiovascular diseases, is an independent risk factor of cardiac morbidity and mortality11 and can be induced by mechanical stress and by humoral factors such as angiotensin II (Ang II).12,13 Several studies have suggested that application of exogenous AM suppresses the development of cardiac hypertrophy and renal damage.14,15 Moreover, mechanical stretch causes AM production in cardiac myocytes,16 whereas Ang II stimulation causes its production in cardiac fibroblasts,17 which suggests that AM serves as a local paracrine or autocrine modulator of cardiac remodeling.
To directly evaluate the function of endogenous AM, we recently generated a strain of AM knockout mice. Homozygous mice (AM–/–) died in utero by embryonic day (E) 13.5,18 but heterozygotes (AM+/–) survived until adulthood. They did exhibit reduced AM expression and elevated blood pressure, however. The aim of the present study was to use this model to examine the effect of endogenous AM expression on cardiac hypertrophy, fibrosis, and renal damage.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Generation of AM Knockout Mice
AM gene targeting was performed as described previously.18 At 12 weeks of age, male mice were used in the experiments. All experiments were performed in accordance with the Declaration of Helsinki and were approved by the University of Tokyo Ethics Committee for Animal Experiments.
Pressure Overload Produced by Aortic Constriction
Pressure overload was produced by constriction of the abdominal aorta as described previously.19 Thirty minutes, 2 hours, or 28 days after ligation, the hearts were removed, weighed, and subjected to further analysis.
Ang II Infusion
Ang II was infused for 14 days into mice with a subcutaneously implanted osmotic minipump (Alzet Co). The delivery rate was 3.2 mg · kg–1 · d–1. To control for the effect of the elevated basal blood pressure on cardiac hypertrophy in AM+/– mice, an antihypertensive drug, hydralazine hydrochloride, was dissolved in the drinking water of some AM+/– mice. This led to a daily intake of 5 mg · kg–1 · d–1, which was sufficient to eliminate the difference in blood pressure between AM+/– and wild-type mice.
In our knockout mice, proadrenomedullin N-terminal 20 peptide (PAMP), another product of the proadrenomedullin gene, is also deleted. To evaluate the effect of that deletion in the present study, in some mice PAMP was also infused at a rate of 20 ng/h along with Ang II.
Cell Culture of Cardiac Myocytes
Cardiac myocytes were harvested from 1-day-old neonatal mice and rats as described previously.20 The cells were cultured for 24 hours, after which the medium was replaced with a complete serum-free medium for 24 hours. The cells were then incubated for an additional 24 hours, with or without 1 µmol/L Ang II. After Ang II treatment, myocyte surface area was measured, and protein synthesis was assayed by measuring 14C-phenylalanine incorporation (see below).
For Western blot analysis, cardiac myocytes from AM+/– or wild-type mice were incubated for 30 minutes with or without 1 µmol/L H7 (Seikagaku Co), an inhibitor of protein kinase C (PKC), and then treated with 1 µmol/L Ang II for 8 minutes. Cardiac myocytes from rat were incubated with 300 nmol/L human recombinant AM with or without 1 µmol/L H89 (Seikagaku Co), an inhibitor of protein kinase A (PKA), and then treated with Ang II.
Incorporation of 14C-Phenylalanine
Protein synthesis by cardiac myocytes was assayed by measuring 14C-phenylalanine (Phe) incorporation. After the cells were incubated with 1 µmol/L Ang II and 0.4 µCi/mL 14C-Phe for 24 hours, they were fixed with 10% TCA. Radioactivity incorporated into the TCA-precipitated material was determined by liquid scintillation counting after solubilization in 1 N NaOH.
Cell Culture of Cardiac Fibroblasts
Cardiac fibroblasts isolated from neonates were cultured for 24 hours, and the serum was starved for 72 hours, after which 1 µmol/L Ang II was added for 48 hours and cell proliferation was quantified with a cell counter (Coulter).
Echocardiographic Analysis
Echocardiography was performed with an HP Sonos 100 (Hewlett-Packard Co) with a 12-MHz imaging transducer as described previously.19,21 Intraventricular septum thickness, left ventricular diastolic diameter, and left ventricular systolic diameter were measured. Ejection fraction (EF) was calculated by the cubed method with the formula EF=[(LVEDD)3–(LVESD)3]/LVEDD3x100 (%).
Histological Analysis
In the heart, perivascular fibrotic area/vascular area ratios were calculated in the sections of left ventricle. The cross-sectional length of cardiac myocytes was also measured. In the kidney, glomerular sclerosis scores were assigned as follows: 0, no changes; 1, lesions involving <25% of the capillary tuft; 2, lesions involving 25% to 49% of the capillary tuft; 3, lesions involving 50% to 75% of the capillary tuft; 4, lesions involving >75% of the capillary tuft.
Statistics
Data are expressed as mean±SEM. Differences within groups were compared with the Fisher protected least significant difference test and Student t test. Values of P<0.05 were considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Characterization of AM+/–
Targeted null mutation of the AM gene is lethal in utero.18 AM+/– mice, by contrast, survived until adulthood and were apparently normal, although levels of cardiac and renal AM mRNA and protein were reduced to approximately half that seen in their wild-type (AM+/+) littermates (Figures 1A and 1B). Plasma cAMP levels were also lower in AM+/– (Figure 1C).
|
Cardiac Hypertrophy Induced by Pressure Overload or Continuous Ang II Infusion
The survival rate after aortic constriction was lower among AM+/– mice (Figure 2A). In particular, the death rate during the first week after the surgery was markedly higher among AM+/– mice (AM+/– 38% versus AM+/+ 18%, P<0.05). An additional 9% of the AM+/– mice died between weeks 2 and 4 after surgery; no wild-type mice died during this period. Accompanying the higher death rate in AM+/– mice were increased levels of BNP gene expression, which has been positively correlated with cardiac dysfunction22 (Figure 2B).
|
Transthoracic echocardiography was performed to visualize the changes in cardiac morphology and function. After aortic constriction, the ventricular wall was thicker in AM+/– mice (intraventricular septum thickness: AM+/+ 1.067±0.02 mm versus AM+/– 1.164±0.02 mm; P<0.01; Figures 3A and 3B). Although left ventricular diastolic diameter was wider in AM+/– mice in the sham-operated group, the difference was offset by the wall thickening after aortic constriction. Ejection fraction was smaller in AM+/– mice after aortic constriction (Figure 3A). When Ang II was infused continuously for 14 days, the ventricular wall in AM+/– mice was also thickened to a greater degree than in wild-type mice (data not shown).
|
Histological Analysis of the Heart After Aortic Constriction and Ang II Infusion
Cardiac hypertrophy induced by aortic constriction or Ang II infusion was exacerbated in AM+/– mice (Figure 4A). In addition, cardiac myocytes from AM+/– mice showed greater cross-sectional lengths (Figure 4B). Although heart weight/body weight ratios were increased in both strains, the change was more prominent in AM+/– mice (Figure 4C).
|
Hydralazine treatment did not affect the cardiac hypertrophy observed in Ang II-treated AM+/– mice (Figure 4D). This suggests that the cardiac hypertrophy seen in Ang II-treated AM+/– mice is a direct effect of AM reduction in the heart rather than an indirect effect of hemodynamic changes. PAMP treatment also failed to affect the cardiac hypertrophy seen in Ang II-treated mice, which indicates that PAMP deletion did not play a significant role in the observed responses (Figure 4D).
Perivascular fibrosis was also more severe in AM+/– mice (Figure 4E). In both banded and Ang II-infused mice, perivascular fibrotic area/vascular area ratios were significantly higher in AM+/– mice (Figure 4F), which indicates that stress-induced proliferation of fibroblasts was enhanced.
Stress-Induced Changes in Cardiac Gene Expression
Hypertrophic responses are thought to involve programmed expression of specific sets of genes.22 After 28 days of aortic constriction, expression of angiotensinogen, ACE, transforming growth factor-ß, and collagen type I was upregulated in the heart, and the effect was more pronounced in AM+/– mice (Figure 5A). At the same time, expression of sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA)-2 was downregulated to a greater degree in AM+/– mice (Figure 5B). Thus, pressure overload caused upregulation of the angiotensin system and other growth factors, which in turn led to cardiac hypertrophy and fibrosis and was associated with cardiac dysfunction in AM+/– mice.
|
We next analyzed the expression of c-fos, an early-response gene, the upregulation of which is closely associated with cardiac hypertrophy.23 As expected, expression of c-fos was upregulated to a greater degree in AM+/– mice than in wild-type mice within 120 minutes (Figure 5C).
AM Suppresses Cardiac Myocyte Hypertrophy and Fibroblast Growth
When Ang II was administered to the cardiac myocytes from AM+/– mice, we observed enlargement of cardiac myocytes (Figures 6A and 6B) that was accompanied by increases in protein synthesis (Figure 6C). Ang II stimulation also enhanced proliferation of fibroblasts isolated from AM+/– mice (Figure 6D) and enhanced collagen type I gene expression (Figure 6E).
|
AM-Induced Changes in Extracellular Signal-Regulated Kinase Activation
The Ras-extracellular signal-regulated kinase (ERK) pathway plays a key role in the induction of early-response genes like c-fos during pressure overload.24 We found ERKs to be activated within 30 minutes after the onset of aortic constriction, and the level of activation was much greater in AM+/– mice (Figure 7A). Treatment with 1 µmol/L Ang II increased ERK phosphorylation in both strains, but the effect was greater in AM+/– mice (Figure 7B). By contrast, the PKC inhibitor H7 suppressed ERK activation in both strains, and the inhibitory effect was more pronounced in AM+/– mice (Figure 7C), which suggests PKC activity is enhanced by Ang II in AM+/– mice.
|
Using rat cardiac myocytes, we confirmed the ability of Ang II to elicit prompt ERK activation and found the effect to be antagonized by exogenous administration of recombinant AM (Figure 7D). Moreover, the inhibitory effect of AM was attenuated by H89, an inhibitor of PKA (Figure 7D). Taken together, these findings suggest that ERK is activated in Ang II-stimulated cardiac myocytes, that AM attenuates this activation, and that the effect of AM is mediated by both activation of PKA and suppression of PKC.
Renal Damage Induced by Continuous Ang II Infusion
After continuous infusion of Ang II, creatinine clearance was lower in AM+/– mice (Figure 8D), and morphological examination revealed much greater damage to the kidneys of AM+/– mice (Figure 8A), which had significantly higher glomerular injury scores (Figure 8B). Increased expression of TGF-ß was also more prominent in AM+/– mice (Figure 8C).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Using AM knockout mice, we have been able to make 3 key observations: (1) that reduced expression of endogenous AM exacerbates the cardiac hypertrophy and fibrosis caused by pressure overload (aortic constriction) or Ang II infusion, leading to diminished cardiac function; (2) that reduced AM expression exacerbates the renal damage caused by Ang II infusion; and (3) that AM suppresses development of cardiac hypertrophy via suppression of ERK activation.
In the present study, we found that although the respective heart, kidney, and body weights were similar in AM+/– and wild-type mice, cardiac and renal expression of AM in AM+/– mice was only approximately half that seen in wild-type mice. Moreover, AM+/– mice exhibited wider left ventricular diastolic diameter than wild-type mice, even under basal conditions, which suggests that AM is necessary for proper development of the heart.
The differences between AM+/– and wild-type mice became much more apparent when stress was applied to the cardiovascular system. Compared with wild-type mice, AM+/– mice exhibited lower survival rates, which were accompanied by higher cardiac brain natriuretic peptide levels; higher heart weight/body weight ratios; greater left ventricular wall thickening; and reprogramming of specific cardiac genes. In particular, downregulation of the SERCA2 gene, which is associated with cardiac dysfunction,25,26 was more apparent in the hearts of AM+/– mice. Using cultured cardiac myocytes from AM+/– mice, we confirmed directly that these cells show more pronounced hypertrophic responses to stressful stimuli. AM+/– mice also exhibited more extensive perivascular fibrosis, and fibroblasts isolated from AM+/– mice showed faster proliferation and enhanced collagen type I gene expression. Taken together, these results suggest that endogenous AM serves as an autocrine or paracrine factor to exert a number of crucial protective effects when the cardiovascular system comes under stress. Consistent with our findings, Caron et al27 recently reported hypertrophic ventricular trabeculae in AM–/– mice, whereas Shimozawa et al28 reported that administration of Ang II with a high-salt diet produced marked perivascular fibrosis in AM+/– mice.
The findings of the present study are also suggestive of the mechanism by which AM exerts its antihypertrophic effects. Because ERKs are known to play a key role in the development of cardiac hypertrophy,29 we examined the extent to which AM-mediated intracellular signaling affected transduction in the ERK. In the hearts of adult mice subjected to pressure overload, as well as in neonatal cardiac myocytes isolated from mice that received acute infusion of Ang II, activation of ERKs was more pronounced in AM+/– mice. AM was originally identified as a peptide that increases cAMP levels in platelets.1 Subsequent experiments in mesangial cells yielded results similar to those reported herein30,31: AM increased cAMP levels, which led to a PKA-dependent decrease in cell proliferation that was associated with decreased ERK activity. It was also shown that delivery of the AM gene attenuates cardiac hypertrophy via production of cAMP32,33 and that AM cAMP-dependently inhibited DNA synthesis and collagen production in cardiac fibroblasts.34 In the present study, PKC inhibition suppressed ERK activation to a greater degree in AM+/– cardiac myocytes. Thus, AM appears to inhibit the development of cardiac hypertrophy, at least in part, by suppressing ERK activation via activation of PKA and inhibition of PKC.
In conclusion, using AM knockout mice, we showed that endogenous AM plays an important role in guarding against cardiovascular damage. We also provide evidences of the potential utility of AM in the treatment of cardiovascular and renal diseases.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Kitamura K, Sakata J, Kangawa K, et al. Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. Biochem Biophys Res Commun. 1993; 194: 720–725.[CrossRef][Medline] [Order article via Infotrieve]
2. Isumi Y, Shoji H, Sugo S, et al. Regulation of adrenomedullin production in rat endothelial cells. Endocrinology. 1998; 139: 838–846.
3. Tsuruda T, Kato J, Kitamura K, et al. Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. Hypertension. 1998; 31: 505–510.
4. Ichiki Y, Kitamura K, Kangawa K, et al. Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett. 1994; 338: 6–10.[CrossRef][Medline] [Order article via Infotrieve]
5. Ehrhart-Bornstein M, Hinson JP, Bornstein SR, et al. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev. 1998; 19: 101–143.
6. Miller MJ, Martinez A, Unsworth EJ, et al. Adrenomedullin expression in human tumor cell lines: its potential role as an autocrine growth factor. J Biol Chem. 1996; 271: 23345–23351.
7. Shichiri M, Kato H, Doi M, et al. Induction of max by adrenomedullin and calcitonin gene-related peptide antagonizes endothelial apoptosis. Mol Endocrinol. 1999; 13: 1353–1363.
8. Samson WK. Adrenomedullin and the control of fluid and electrolyte homeostasis. Annu Rev Physiol. 1999; 61: 363–389.[CrossRef][Medline] [Order article via Infotrieve]
9. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000; 21: 138–167.
10. Sakata J, Shimokubo T, Kitamura K, et al. Molecular cloning and biological activities of rat adrenomedullin, a hypotensive peptide. Biochem Biophys Res Commun. 1993; 195: 921–927.[CrossRef][Medline] [Order article via Infotrieve]
11. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322: 1561–1566.[Abstract]
12. Komuro I, Katoh Y, Kaida T, et al. Mechanical loading stimulates cell hypertrophy and specific gene expression in cultured rat cardiac myocytes: possible role of protein kinase C activation. J Biol Chem. 1991; 266: 1265–1268.
13. Baker KM, Aceto JF. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol. 1990; 259: H610–H618.[Medline] [Order article via Infotrieve]
14. Dobrzynski E, Wang C, Chao J, et al. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 2000; 36: 995–1001.
15. Nishikimi T, Mori Y, Kobayashi N, et al. Renoprotective effect of chronic adrenomedullin infusion in Dahl salt-sensitive rats. Hypertension. 2002; 39: 1077–1082.
16. Tsuruda T, Kato J, Kitamura K, et al. Enhanced adrenomedullin production by mechanical stretching in cultured rat cardiomyocytes. Hypertension. 2000; 35: 1210–1214.
17. Tsuruda T, Kato J, Kitamura K, et al. An autocrine or a paracrine role of adrenomedullin in modulating cardiac fibroblast growth. Cardiovasc Res. 1999; 43: 958–967.
18. Shindo T, Kurihara Y, Nishimatsu H, et al. Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation. 2001; 104: 1964–1971.
19. Harada K, Komuro I, Shiojima I, et al. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation. 1998; 97: 1952–1959.
20. Komuro I, Kaida T, Shibazaki Y, et al. Stretching cardiac myocytes stimulates protooncogene expression. J Biol Chem. 1990; 265: 3595–3598.
21. Kojima M, Shiojima I, Yamazaki T, et al. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation. 1994; 89: 2204–2211.
22. Saul L, Shatzer M. B-type natriuretic peptide testing for detection of heart failure. Crit Care Nurs Q. 2003; 26: 35–39.[Medline] [Order article via Infotrieve]
23. Osaki J, Haneda T, Sakai H, et al. cAMP-mediated c-fos expression in pressure-overloaded acceleration of protein synthesis in adult rat heart. Cardiovasc Res. 1997; 33: 631–640.
24. Aikawa R, Komuro I, Nagai R, et al. Rho plays an important role in angiotensin II-induced hypertrophic responses in cardiac myocytes. Mol Cell Biochem. 2000; 212: 177–182.[CrossRef][Medline] [Order article via Infotrieve]
25. Frank KF, Bolck B, Erdmann E, et al. Sarcoplasmic reticulum Ca2+-ATPase modulates cardiac contraction and relaxation. Cardiovasc Res. 2003; 57: 20–27.
26. Nakayama H, Otsu K, Yamaguchi O, et al. Cardiac-specific overexpression of a high Ca2+ affinity mutant of SERCA2a attenuates in vivo pressure overload cardiac hypertrophy. FASEB J. 2003; 17: 61–63.
27. Caron KM, Smithies O. Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional adrenomedullin gene. Proc Natl Acad Sci U S A. 2001; 98: 615–619.
28. Shimosawa T, Shibagaki Y, Ishibashi K, et al. Adrenomedullin, an endogenous peptide, counteracts cardiovascular damage. Circulation. 2002; 105: 106–111.
29. Indolfi C, Di Lorenzo E, Perrino C, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation. 2002; 106: 2118–2124.
30. Osajima A, Kato H, Uezono Y, et al. Adrenomedullin inhibits transmural pressure induced mesangial cell proliferation through activation of protein kinase A. Nephron. 1999; 83: 352–357.[CrossRef][Medline] [Order article via Infotrieve]
31. Parameswaran N, Nambi P, Hall CS, et al. Adrenomedullin decreases extracellular signal-regulated kinase activity through an increase in protein phosphatase-2A activity in mesangial cells. Eur J Pharmacol. 2000; 388: 133–138.[CrossRef][Medline] [Order article via Infotrieve]
32. Zhang JJ, Yoshida H, Chao L, et al. Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive Dahl salt-sensitive rats. Hum Gene Ther. 2000; 11: 1817–1827.[CrossRef][Medline] [Order article via Infotrieve]
33. Wang C, Dobrzynski E, Chao J, et al. Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. Am J Physiol Renal Physiol. 2001; 280: F964–F971.
34. Horio T, Nishikimi T, Yoshihara F, et al. Effects of adrenomedullin on cultured rat cardiac myocytes and fibroblasts. Eur J Pharmacol. 1999; 382: 1–9.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  D. L. Sackett, L. Ozbun, E. Zudaire, L. Wessner, J. M. Chirgwin, F. Cuttitta, and A. Martinez Intracellular Proadrenomedullin-Derived Peptides Decorate the Microtubules and Contribute to Cytoskeleton Function Endocrinology, June 1, 2008; 149(6): 2888 - 2898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Dackor, K. Fritz-Six, W. P. Dunworth, C. L. Gibbons, O. Smithies, and K. M. Caron Hydrops fetalis, cardiovascular defects, and embryonic lethality in mice lacking the calcitonin receptor-like receptor gene. Mol. Cell. Biol., April 1, 2006; 26(7): 2511 - 2518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Miyashita, H. Itoh, H. Arai, T. Suganami, N. Sawada, Y. Fukunaga, M. Sone, K. Yamahara, T. Yurugi-Kobayashi, K. Park, et al. The Neuroprotective and Vasculo-Neuro-Regenerative Roles of Adrenomedullin in Ischemic Brain and Its Therapeutic Potential Endocrinology, April 1, 2006; 147(4): 1642 - 1653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Vallon, D. Y. Huang, F. Grahammer, A. W. Wyatt, H. Osswald, P. Wulff, D. Kuhl, and F. Lang SGK1 as a determinant of kidney function and salt intake in response to mineralocorticoid excess Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R395 - R401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nishikimi, K. Tadokoro, K. Akimoto, Y. Mori, Y. Ishikawa, K. Ishimura, T. Horio, K. Kangawa, and H. Matsuoka Response of adrenomedullin system to cytokine in cardiac fibroblasts-role of adrenomedullin as an antifibrotic factor Cardiovasc Res, April 1, 2005; 66(1): 104 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tsuruda, J. Kato, K. Hatakeyama, H. Masuyama, Y.-N. Cao, T. Imamura, K. Kitamura, Y. Asada, and T. Eto Antifibrotic effect of adrenomedullin on coronary adventitia in angiotensin II-induced hypertensive rats Cardiovasc Res, March 1, 2005; 65(4): 921 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Swaney, D. M. Roth, E. R. Olson, J. E. Naugle, J. G. Meszaros, and P. A. Insel Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase PNAS, January 11, 2005; 102(2): 437 - 442. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||